Top 10 Undervalued Stocks To Own For 2019

Small-cap stocks can deliver explosive gains — or sizable losses. Choose well, and these high-risk yet potentially high-reward stocks can deliver multibagger returns and turbocharge your portfolio’s overall performance. But choose poorly, and a small-cap stock can produce painful losses, up to and including a complete loss of capital should the business be forced into bankruptcy.

That’s why it’s so important to invest in only the strongest of these companies — those that possess the best business models and enjoy the largest growth opportunities. In this regard, here’s one of the most intriguing small-cap stocks available in the market today.

This small-cap stock can grow into something much larger in the years ahead. Image source: Getty Images.

In the mold of a young Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B), Boston Omaha (NASDAQ:BOMN) is a small conglomerate designed to generate attractive long-term returns through the consistent acquisition of undervalued assets. Its current businesses include insurance, real estate, and advertising, and the company plans to expand within these areas and others via both acquisitions and organic growth.

Top 10 Undervalued Stocks To Own For 2019: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Max Byerly]

    Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

    Get Oncomed Pharmaceuticals alerts:

    Recent Technicals: OncoMed Pharmaceuticals (NASDAQ: OMED) (reagentsglobalmarket.com) OncoMed Pharmaceuticals, Inc. (NasdaqGS:OMED) Book to Market Valuation Stands at 0.479899 (vassarnews.com) Zacks: Analysts Expect Oncomed Pharmaceuticals Inc (OMED) Will Announce Quarterly Sales of $7.97 Million (americanbankingnews.com) Oncomed Pharmaceuticals Inc (OMED) Expected to Post Earnings of -$0.20 Per Share (americanbankingnews.com) Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)

    Several brokerages have weighed in on OMED. Zacks Investment Research cut shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 21st. ValuEngine raised shares of Oncomed Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $4.30.

Top 10 Undervalued Stocks To Own For 2019: American Superconductor Corporation(AMSC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Media coverage about American Superconductor (NASDAQ:AMSC) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. American Superconductor earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 47.29145037575 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

  • [By Max Byerly]

    News stories about American Superconductor (NASDAQ:AMSC) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. American Superconductor earned a news impact score of 0.18 on Accern’s scale. Accern also gave media headlines about the technology company an impact score of 46.824635153043 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Shane Hupp]

    News stories about American Superconductor (NASDAQ:AMSC) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. American Superconductor earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned headlines about the technology company an impact score of 47.5442417425226 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on American Superconductor (AMSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    American Superconductor (NASDAQ:AMSC) had its price target upped by investment analysts at B. Riley from $6.00 to $7.00 in a research note issued on Monday. The firm presently has a “neutral” rating on the technology company’s stock. B. Riley’s price objective suggests a potential upside of 10.06% from the company’s current price.

  • [By Shane Hupp]

    American Superconductor (NASDAQ:AMSC) last issued its earnings results on Tuesday, February 5th. The technology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.18. The company had revenue of $14.13 million during the quarter, compared to the consensus estimate of $15.13 million. American Superconductor had a net margin of 52.83% and a negative return on equity of 29.09%. As a group, analysts anticipate that American Superconductor Co. will post -1.06 earnings per share for the current fiscal year.

Top 10 Undervalued Stocks To Own For 2019: Capital Senior Living Corporation(CSU)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Capital Senior Living (CSU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    State of New Jersey Common Pension Fund D lessened its stake in shares of Capital Senior Living (NYSE:CSU) by 5.3% in the first quarter, Holdings Channel reports. The institutional investor owned 180,000 shares of the company’s stock after selling 10,000 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Capital Senior Living were worth $1,935,000 as of its most recent filing with the SEC.

  • [By Shane Hupp]

    $900.00 upgraded shares of Constellation Software (TSE:CSU) from a neutral rating to an outperform rating in a report issued on Tuesday morning.

    Other equities analysts have also issued reports about the stock. National Bank Financial lifted their price target on shares of Constellation Software from C$850.00 to C$875.00 and gave the stock a sector perform rating in a report on Friday, April 27th. CIBC lifted their price target on shares of Constellation Software from C$865.00 to C$900.00 in a report on Friday, April 27th. lifted their price target on shares of Constellation Software to C$980.00 in a report on Thursday, April 26th. Finally, Scotiabank lifted their price target on shares of Constellation Software from C$880.00 to C$940.00 and gave the stock an outperform rating in a report on Tuesday, April 24th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of C$901.88.

  • [By Stephan Byrd]

    Media stories about Capital Senior Living (NYSE:CSU) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Capital Senior Living earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.062391046142 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Top 10 Undervalued Stocks To Own For 2019: Colony Bankcorp Inc.(CBAN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Media stories about Colony Bankcorp (NASDAQ:CBAN) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Colony Bankcorp earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the financial services provider an impact score of 48.3992787299045 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

  • [By Logan Wallace]

    Headlines about Colony Bankcorp (NASDAQ:CBAN) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Colony Bankcorp earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the financial services provider an impact score of 46.0420470648687 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Max Byerly]

    Media headlines about Colony Bankcorp (NASDAQ:CBAN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Colony Bankcorp earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the financial services provider an impact score of 46.5935973221915 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Undervalued Stocks To Own For 2019: Terex Corporation(TEX)

Advisors’ Opinion:

  • [By Rich Smith]

    All year long, Terex (NYSE:TEX) stock has been pacing the S&P 500’s performance — and even leading it a bit, up 15% to the market’s 14% gain. Today, shares are moving in and out of negative territory.

  • [By Lee Samaha]

    Shares in construction equipment company Terex Corporation (NYSE:TEX) fell 12.2% in August, according to data from S&P Global Market Intelligence. Since most of the fall occurred in the immediate aftermath of the second-quarter earnings report, which came out on the last day of July, it’s reasonable to conclude that investors didn’t like something about Terex’s presentation.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Terex (TEX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Terex (TEX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Asset Management One Co. Ltd. acquired a new stake in Terex Co. (NYSE:TEX) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 9,770 shares of the industrial products company’s stock, valued at approximately $365,000.

Top 10 Undervalued Stocks To Own For 2019: Knowles Corporation(KN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Knowles (KN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    These are some of the news articles that may have impacted Accern Sentiment’s scoring:

    Get Knowles alerts:

    Head to Head Contrast: Knowles (KN) vs. Sony (SNE) (americanbankingnews.com) Knowles (KN) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com) Four seniors nab scholarships from Siouxland Officials Association (siouxcityjournal.com) When is Who Dares Wins on BBC One tonight, how old is host Nick Knowles and how does the game show work? (thesun.co.uk) Local students learn the art of architecture (dailytidings.com)

    KN has been the subject of several research analyst reports. Craig Hallum restated a “buy” rating and set a $17.00 price target (down from $20.00) on shares of Knowles in a research report on Thursday, February 8th. Zacks Investment Research lowered Knowles from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. ValuEngine lowered Knowles from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. JPMorgan Chase lowered their price target on Knowles from $16.00 to $13.50 and set a “neutral” rating for the company in a research report on Tuesday, April 24th. Finally, Lake Street Capital lowered their price target on Knowles from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $17.29.

  • [By Lisa Levin]

    Shares of Knowles Corporation (NYSE: KN) got a boost, shooting up 15 percent to $12.83 as the company reported Q1 results.

    SVB Financial Group (NASDAQ: SIVB) shares were also up, gaining 19 percent to $305.90 following strong quarterly results.

Top 10 Undervalued Stocks To Own For 2019: Vanguard Extended Market ETF (VXF)

Advisors’ Opinion:

  • [By Max Byerly]

    Regal Investment Advisors LLC grew its stake in shares of Vanguard Extended Market ETF (NYSEARCA:VXF) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,927 shares of the company’s stock after purchasing an additional 311 shares during the quarter. Regal Investment Advisors LLC’s holdings in Vanguard Extended Market ETF were worth $1,190,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Vanguard Extended Market ETF (NYSEARCA:VXF) declared a quarterly dividend on Thursday, June 28th, Wall Street Journal reports. Investors of record on Friday, June 29th will be given a dividend of 0.3704 per share on Tuesday, July 3rd. This represents a $1.48 annualized dividend and a yield of 1.26%. The ex-dividend date is Thursday, June 28th. This is an increase from Vanguard Extended Market ETF’s previous quarterly dividend of $0.32.

  • [By Joseph Griffin]

    MML Investors Services LLC lowered its position in shares of Vanguard Extended Market ETF (NYSEARCA:VXF) by 14.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,370 shares of the company’s stock after selling 1,926 shares during the quarter. MML Investors Services LLC’s holdings in Vanguard Extended Market ETF were worth $1,268,000 as of its most recent filing with the SEC.

Top 10 Undervalued Stocks To Own For 2019: Euro FX(P)

Advisors’ Opinion:

  • [By Rick Munarriz]

    Pandora (NYSE:P) is hitting the “last dance” phase of its life as a stand-alone public company, and if anyone wants to outbid Sirius XM Radio (NASDAQ:SIRI) for the streaming music pioneer they better speak up soon. Sirius XM announced the all-stock deal initially valued at $3.5 billion on Monday. 

  • [By Timothy Green]

    Music-streaming company Pandora (NYSE:P) finally launched an on-demand subscription service in early 2017. Pandora Premium, priced at $9.99 per month, directly competes with Spotify and Apple Music. The company’s goal is to convert a significant chunk of its ad-supported listener base into subscribers. In addition to the new on-demand service, Pandora offers an ad-free version of its core internet radio experience for $4.99 per month.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of Pandora Media (NYSE:P) from a hold rating to a buy rating in a report published on Tuesday.

    A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Pandora Media from a hold rating to a buy rating and set a $9.25 target price on the stock in a research report on Saturday, August 4th. Wedbush set a $10.00 target price on Pandora Media and gave the stock a buy rating in a research report on Wednesday, August 1st. Canaccord Genuity set a $10.00 target price on Pandora Media and gave the stock a buy rating in a research report on Wednesday, August 1st. Susquehanna Bancshares lifted their target price on Pandora Media from $7.00 to $8.00 and gave the stock a neutral rating in a research report on Wednesday, August 1st. Finally, BMO Capital Markets lifted their target price on Pandora Media from $12.00 to $13.00 and gave the stock an outperform rating in a research report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $7.85.

Top 10 Undervalued Stocks To Own For 2019: TherapeuticsMD, Inc.(TXMD)

Advisors’ Opinion:

  • [By Joseph Griffin]

    JPMorgan Chase & Co. initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Friday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $11.00 price target on the stock.

  • [By Max Byerly]

    TherapeuticsMD Inc (NASDAQ:TXMD) – Equities researchers at Cantor Fitzgerald reduced their FY2018 earnings estimates for shares of TherapeuticsMD in a research report issued on Tuesday, August 14th. Cantor Fitzgerald analyst W. Tanner now expects that the company will post earnings per share of ($0.68) for the year, down from their previous estimate of ($0.62). Cantor Fitzgerald currently has a “Overweight” rating and a $27.00 target price on the stock.

  • [By Shane Hupp]

    Oppenheimer set a $14.00 price objective on TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the stock.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Feroldi]

    After receiving some analyst love, shares of TherapeuticsMD (NASDAQ:TXMD), a commercial-stage biopharma focused on women’s health, rose 13% as of 3:35 p.m. EDT Tuesday.

  • [By Max Byerly]

    TherapeuticsMD Inc (NASDAQ:TXMD) – Investment analysts at Oppenheimer increased their Q3 2018 EPS estimates for shares of TherapeuticsMD in a research report issued to clients and investors on Tuesday, June 5th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.09). Oppenheimer currently has a “Buy” rating and a $12.00 price target on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q4 2018 earnings at ($0.03) EPS, FY2018 earnings at ($0.32) EPS, FY2019 earnings at ($0.10) EPS, FY2020 earnings at $0.22 EPS, FY2021 earnings at $0.44 EPS and FY2022 earnings at $0.70 EPS.

Top 10 Undervalued Stocks To Own For 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    Galapagos N.V. (NASDAQ:GLPG) is developing new triplet combination therapies with AbbVie (NYSE:ABBV) for cystic fibrosis that the two companies hope can challenge Vertex Pharmaceuticals (NASDAQ:VRTX) someday. Unfortunately, the results reported yesterday from a mid-stage study did not inspire confidence. Is Galapagos’ plan to tackle cystic fibrosis a failure? 

  • [By Keith Speights]

    Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock came after Galapagos N.V. (NASDAQ:GLPG) announced disappointing results Thursday evening from a phase 2 clinical study evaluating C2 corrector GLPG2737 in treating cystic fibrosis (CF).

  • [By Max Byerly]

    Dorsey Wright & Associates lessened its stake in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 33.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,744 shares of the biotechnology company’s stock after selling 32,800 shares during the period. GALAPAGOS NV/S accounts for approximately 1.3% of Dorsey Wright & Associates’ holdings, making the stock its 17th biggest position. Dorsey Wright & Associates owned 0.13% of GALAPAGOS NV/S worth $7,391,000 at the end of the most recent reporting period.

  • [By Todd Campbell]

    Eager to participate in the multibillion-dollar market for autoimmune-disease treatments, Gilead Sciences licensed filgotinib from Galapagos NV (NASDAQ:GLPG) in 2015. 

Leave a Reply

Your email address will not be published. Required fields are marked *